AAVXF:OTCMKTS
Abivax SA
US$ 139,00
0,00%
(0,00) 1D
9 jul, 09:30:01 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor AAVXF genereren…
Beursw.
6,77 mld.
Gem. vol.
0,00
Volume
0,00
52 wk hoog
US$ 139,00
52 wk laag
US$ 71,26
Bèta
3,09
Uitstaande aandelen
87,53 mln.
Aantal medewerkers
98
Beursw.
6,77 mld.
Gem. vol.
0,00
Volume
0,00
52 wk hoog
US$ 139,00
52 wk laag
US$ 71,26
Bèta
3,09
Uitstaande aandelen
87,53 mln.
Aantal medewerkers
98
Nieuwsartikelen
Van webbronnen en nieuwspartners
Idéal Investisseur
·
8 uur geleden
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
https://www.dars.gov.et/
·
4 dagen geleden
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profiel
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Over Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Medewerkers98
Opgericht4 dec 2013
Hoofdkantoor-
Sector-
Websiteabivax.com